BridgeBio Pharma: FDA Endorsement and Stable Price Target Bolster Buy Rating
Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...
ETF Daily News22h
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby™ (acoramidis)’
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Massachusetts Financial Services Co. MA
Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...
BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
ETF Daily News1d
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $48.00 at Scotiabank
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price raised by Scotiabank from $45.00 to $48.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector ...
Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
BridgeBio Pharma (BBIO) Receives a Hold from Oppenheimer
Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...
BridgeBio price target raised to $48 from $45 at Scotiabank
Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $48 from $45 and keeps an Outperform rating on the ...
BridgeBio price target raised to $45 from $42 at BofA
BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the ...
BridgeBio Pharma (BBIO) Receives a Buy from Cantor Fitzgerald
In a report released on November 23, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on BridgeBio Pharma (BBIO – Research ...
TD Cowen Remains a Buy on BridgeBio Pharma (BBIO)
TD Cowen analyst Tyler Van Buren maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares closed last ...
GEN2d
Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...